Four top executives of the Maryland company were awarded stock options worth more than $100 million and contingent on the vaccine reaching a testing benchmark, not market.
Iconic One Theme | Powered by Wordpress
Four top executives of the Maryland company were awarded stock options worth more than $100 million and contingent on the vaccine reaching a testing benchmark, not market.